Abstract
BACKGROUND: The prognosis for acute myeloid leukemia (AML) remains poor, underscoring the need for a deeper understanding of its underlying molecular mechanisms. AIM: To assess the significance of SOX11 gene expression in the clinical features, response to treatment, and survival outcomes of adult patients with AML. METHODS: This retrospective study enrolled 102 adults with AML. SOX11 gene expression in bone marrow samples was measured using real-time PCR. Data were correlated to the patients' clinical features, response to treatment, and survival rates. RESULTS: Increased SOX11 expression was significantly associated with the presence of the FLT3-ITD mutation (P < 0.001), the FAB-M2 subtype (P = 0.008), and cytogenetic abnormalities (P = 0.011). However, no significant association was found between SOX11 expression and other clinical laboratory parameters, complete remission, disease-free survival, or overall survival. CONCLUSION: SOX11 expression may serve as a marker to identify specific subsets of AML patients who could benefit from intensive targeted chemotherapy.